All EuBiologics Co., LTD articles
-
NewsTyphoid conjugate vaccine demonstrates strong safety and immunogenicity: Results from Phase 3 study
PATH and EuBiologics Co., LTD have announced Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.® Source: CDC/ Armed Forces Institute of Pathology, Charles N. Farmer This photomicrograph reveals some of the histopathology exhibited in a lymph node tissue ...